![]() Seagen Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. | ![]() Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. | Metys Pharmaceuticals Metys Pharmaceuticals is a company that provides treatment for chemotherapy-induced peripheral neuropathy, a side effect of several cancer treatments. | PIN Pharma PIN Pharma is a biopharmaceutical company focused on developing broad-base immuno-modulatory therapies, linking the innate and adaptive immune systems. | |
Founding Date | Founding Date 1998 | Founding Date 1982 | Founding Date 2013 | Founding Date 2011 |
Type | Type Subsidiary | Type Subsidiary | Type Private | Type Private |
Tags | ||||
Locations | Locations Bothell, US HQ Mississauga, CA Hørsholm, DK Rueil Malmaison, FR München, DE Milano, IT Schiphol, NL see more | Locations Morris Plains, US HQ | Locations Basel, CH HQ Basel, CH | Locations New York, US HQ |
Employees | Employees 3,25622% increase | Employees 102 | Employees 2 | Employees 1 |
Financial | ||||
Revenue (est.) | Revenue (est.) $2b (FY, 2022) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $410.1m (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $1.6b (FY, 2022) | Gross profit $295k (FY, 2019) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($610.3m) (FY, 2022) | Net income ($357.3m) (FY, 2019) | Net income N/A | Net income N/A |
Funding | ||||
Total funding raised | Total funding raised $ 164m | Total funding raised $ 30m | Total funding raised N/A | Total funding raised N/A |
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View companyMetys Pharmaceuticals is a company that provides treatment for chemotherapy-induced peripheral neuropathy, a side effect of several cancer treatments.
View companyPIN Pharma is a biopharmaceutical company focused on developing broad-base immuno-modulatory therapies, linking the innate and adaptive immune systems.
View company